The vaccine is tested for efficacy in Coronavirus infections
COVID-19, which is spread by the novel Coronavirus Sars-CoV-2 respiratory infection, resolved internationally. Worldwide research institutes are working on the development of a vaccine against the Virus. Until such is available, could help a vaccine has been developed against tuberculosis.
More and more people are wondering what time is the first vaccine against COVID-19 is available. Recently, it was reported that a research Institute in Israel that could provide such a in just a few weeks. German Researchers are working on vaccines. In the meantime, it could help to an agent that was developed for another disease.
Study at several clinics in Germany
The history of the Coronavirus pandemic will greatly depend on how quickly drugs or vaccines can be developed against the SARS-Co Virus 2.
According to a communication from the Max-Planck-Gesellschaft (MPG), researchers examine the end in at least one Phase III study, whether originally by scientists at the Max-Planck-Institute for infection biology, tuberculosis developed vaccine candidate VPM1002 is also in the case of infection with SARS-CoV-2 to be effective.
The information suggests that the large-scale study is to be conducted at several clinics in Germany and will include the elderly and health care Workers are particularly at risk of the disease.
VPM1002 could help to bridge the time until a vaccine is specific against SARS-CoV-2 to be effective.
Protection against virus infections of the respiratory tract
How the MPG is explained, based VPM1002 on a the beginning of the 20th century. Century developed the vaccine called BCG. Studies in mice show that BCG can protect the vaccine not only against tuberculosis, but also against viral infections of the respiratory tract.
As a result, flu-diseased mice have less Influenza A viruses in the blood, if they have been previously vaccinated with BCG. As a result, the animals showed less damage to the lungs. Vaccination with BCG increased the further studies according to the resistance of the animals to other viruses such as herpes virus type 1 and 2.
In addition, there are from the Netherlands and the UK, evidence that BGC could help as a so-called Bystander vaccine against the new Coronavirus. Vaccination with BCG-activated, apparently the immune system against a virus infection. The vaccine reduces the risk of serious disease and reduces rates death.
The vaccine contains weakened tuberculosis-like bacteria
As it says in the message, contains VPM1002 attenuated tuberculosis-like bacteria. These are genetically modified so that immune cells can recognize them better.
Originally in the Berlin Max-Planck-Institute for infection biology, of the group of Stefan H. E. Kaufmann, have developed a vaccine candidate protects more effectively against tuberculosis than the old vaccine and is to be used in the newborn as well as booster vaccination in adults.
Latest studies have shown that VPM1002 also can diseases in cancer be effective, and a return of bladder tumors to prevent.
Symptoms of infection with the new Coronavirus mitigate better
Researchers have investigated this further development of the BCG vaccine in a series of studies in mice and several clinical studies. So about 2018 has confirmed in a Phase II study that VPM1002 of newborns is well tolerated and effective.
According to the figures, the vaccine is currently being tested in a further Phase III study of adult subjects in India. This should be completed by mid-2020. “The results show that vaccination with VPM1002 is safe and more effective than a standard vaccination with BCG,” explains Stefan H. E. Kaufmann.
The higher safety profile of VPM1002 and the improved effectiveness can hope that the new vaccine can also reduce the symptoms of infection with the new Coronavirus is better than the BCG vaccine.
“On top of that VPM1002 can be manufactured using the latest production methods,” explains Adar C. Poonawalla, the manufacturer, and managing Director of Serum Institute of India. “So could be deployed within a very short time, millions of doses.”
Promising talks with the authorities
The partners in the vaccine project Management (VPM) and Serum Institute of India, have already led to promising talks with the authorities, a Phase-III-to carry out the study in Germany with VPM1002 and to investigate the efficacy of the vaccine in older people and in health care.
“These population groups are particularly affected by the current pandemic,” says Leander Grode Executive Director of the VPM “and could therefore benefit in particular from vaccination with VPM1002”.
In the case of a positive result of VPM1002 could contribute to the MPG to the health to relieve systems, until a vaccine is available that is specific against SARS-CoV-2 to be effective.
The Max-Planck-Gesellschaft has awarded the license for the vaccine as early as 2004, the company Vakzine Projekt Management (VPM). As of 2012, the company developed the vaccine along with Serum Institute of India, one of the largest vaccine manufacturers in the world. This company has taken over the VPM, in the meantime, the majority of. (ad)